Portal de Periódicos da CAPES

Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer

2010; Elsevier BV; Volume: 125; Issue: 1-2 Linguagem: Inglês

10.1016/j.jsbmb.2010.09.003

1879-1220

Lucy J. Schmidt, Donald J. Tindall,

Prostate Cancer Treatment and Research

Steroid 5 alpha-reductase inhibitors (5ARIs) have been approved for use clinically in treatment of benign prostate hyperplasia (BPH) and accompanying lower urinary tract symptoms (LUTS) and have also been evaluated in clinical trials for prevention and treatment of prostate cancer. There are currently two steroidal inhibitors in use, finasteride and dutasteride, both with distinct pharmacokinetic properties. This review will examine the evidence presented by various studies supporting the use of these steroidal inhibitors in the prevention and treatment of prostate disease. Article from the Special issue on Targeted Inhibitors.